Related Experiment Video
Updated: Aug 3, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies
G Aguirre1, M Boiani, H Cerecetto
1Departamento de Química Orgánica, Facultad de Química y Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay.
Abstract:
Furoxan derivatives with in vitro cytotoxic activity were investigated as antitumoral agents in vivo. The compounds were tested in murine models of both CCRFS-180 II sarcoma and mammary adenocarcinoma. Two of the furoxan derivatives considered here, 3-formyl-4-phenyl-1,2,5-oxadiazole N2-oxide and 3-carbonitrile-4-phenyl-1,2,5-oxadiazole N2-oxide, present in vivo antitumoral activity. They were able to produce more than 90% of tumoral necrosis under the experimental protocol of administration and posology employed. NO-releasing capacity of furoxans may explain the anti-neoplastic activity of these compounds.
Insights
Two furoxan derivatives demonstrated significant in vivo antitumoral activity, causing over 90% tumor necrosis in murine models. Their nitric oxide-releasing capacity likely contributes to this anti-neoplastic effect.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Oncology
Background:
- Furoxan derivatives exhibit in vitro cytotoxic activity.
- Investigating novel antitumoral agents is crucial for cancer therapy.
Purpose of the Study:
- To evaluate the in vivo antitumoral efficacy of specific furoxan derivatives.
- To explore the potential of furoxans as novel cancer chemotherapeutics.
Main Methods:
- Testing furoxan derivatives in murine models of CCRFS-180 II sarcoma and mammary adenocarcinoma.
- Assessing tumor necrosis and overall antitumoral effect.
Main Results:
- Two furoxan derivatives, 3-formyl-4-phenyl-1,2,5-oxadiazole N2-oxide and 3-carbonitrile-4-phenyl-1,2,5-oxadiazole N2-oxide, showed significant in vivo antitumoral activity.
- These compounds induced over 90% tumoral necrosis in the tested murine models.
- Nitric oxide (NO)-releasing capacity is proposed as the mechanism underlying the observed anti-neoplastic activity.
Conclusions:
- Furoxan derivatives possess potent in vivo antitumoral properties.
- The NO-releasing mechanism is a promising avenue for developing new anticancer drugs.
